Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Pfizer claims new $3.2bn COVID jab deal with US government

From trial design for patients to trial design with patients: a key topic at DIA ’22

Merck launches accelerator programme for AI startups

FDA rejection of Spero’s tebipenem ‘raises resistance threat’

Pfizer seeks to overturn three RSV vaccine patents held by GSK

FLT3 inhibitor

Daiichi-Sankyo-sign

News/ News/ News/ Oncology/ R&D

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

Phil Taylor acute myeloid leukaemia, Astellas, Daiichi Sankyo, EHA 2022, FLT3 inhibitor, Novartis, quizartinib, Rydapt, Xospata 0 Comment

Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the

X

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

https://pharmaphorum.com/news/eha-survival-data-sets-daiichi-sankyos-quizartinib-back-on-track/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Novartis will shed 7% of workforce in restructuring, say reports
Pfizer seeks to overturn three RSV vaccine patents held by GSK
Gilead tries again with twice-yearly HIV drug lenacapavir
Celebrations for ASMD community as EU clears Sanofi's Xenpozyme
Sanofi extends Health2Sync digital diabetes partnership to Japan

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com